CLX
The Clorox Company
CLX's fundamentals are mixed, but it looks cheap: trading at 20x earnings, below its usual 34x. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
CLX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Weak |
CLX's revenue is currently healthy, and its profitability and cash flow are stable, but its balance sheet is weak.
CLX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $108 | -0.3% |
| Forward | 19x | $108 | — |
| Current | 20x | $108 | — |
| Fair | 34x | $187 | +73% |
| Expensive | 73x | $403 | +273% |
Historical ranges are pointers, not guarantees.
CLX's PE is in its cheap range at 20x. On analysts' estimates for next year's earnings, today's price would be 19x.
CLX Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Growth | |
| Weakening | |
| Moderate | |
| Low |
Analysts expect CLX's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.73 | +3.2% |
| Q3 2026 | $5.55 | -13% |
| Q2 2026 | $4.81 | -26% |
| Q1 2026 | $6.16 | +10% |
| Q4 2025 | $6.12 | +67% |
| Q3 2025 | $6.37 | +121% |
| Q2 2025 | $6.52 | +190% |
| Q1 2025 | $5.58 | +188% |
| Q4 2024 | $3.67 | +473% |
CLX's earnings per share have fallen from their peak: $5.55 over the past year, against $9.55 in late 2020.
CLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +33% |
| Q2 2026 | $1.9B | -2% |
| Q1 2026 | $1.7B | +0.1% |
| Q4 2025 | $1.7B | -0.8% |
| Q3 2025 | $1.4B | -19% |
| Q2 2025 | $2B | +4.5% |
| Q1 2025 | $1.7B | -8% |
| Q4 2024 | $1.7B | -15% |
CLX's revenue is growing: $1.9B last quarter, up 33% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +3.4 points |
| Q2 2026 | 11% | -9.7 points |
| Q1 2026 | 15% | +0.1 points |
| Q4 2025 | 13% | -1.2 points |
| Q3 2025 | 7.5% | -2.6 points |
| Q2 2025 | 21% | +6.2 points |
| Q1 2025 | 15% | +18 points |
| Q4 2024 | 14% | +7.2 points |
CLX's operating margin was 11% last quarter, up 3.4 points from the same quarter a year ago.
CLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $105M | +84% |
| Q2 2026 | $244M | +11% |
| Q1 2026 | -$165M | -171% |
| Q4 2025 | $269M | +112% |
| Q3 2025 | $57M | -69% |
| Q2 2025 | $219M | -15% |
| Q1 2025 | $233M | +83% |
| Q4 2024 | $127M | +26% |
CLX still generates free cash flow, though less than at its 2020 peak: $453M over the past year.
CLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -105K shares |
| 1 year | -0.8% | -991K shares |
| 3 years | -2.1% | -2.6M shares |
| 5 years | -1.6% | -2M shares |
| Available history | -3.8% | -4.9M shares |
CLX has 122M diluted shares, down 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $127M |
| Q3 2025 | $129M |
| Q2 2025 | $75M |
| Q1 2025 | — |
| Q4 2024 | $150M |
CLX spent $127M buying back its own shares over the past year, down 64% from the year before.
CLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 4.7x | High |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 2.1x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 2.7x | Moderate |
CLX's net debt is about 4.3 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
CLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 64.3 | Neutral |
CLX's weekly RSI is 62 (neutral) and its Stochastic is 64 (neutral).
CLX PE vs Consumer Defensive Sector
| Metric | CLX | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 19x | 0.1% above |
| PE % | 17 | 18 | 1 pt below |
CLX is trading at 20x earnings, in line with the Consumer Defensive sector's median of 19x.
CLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $89.7 | 21% above |
| 20 week MA | $94.1 | 15% above |
| 50 week MA | $100.2 | 8% above |
| 100 week MA | $116.9 | 7.5% below |
| 200 week MA | $133.4 | 19% below |
CLX has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 19% below its 200-week average.
CLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $153.5 | $203.8 | +33% |
| 2021 | $203.8 | $169.8 | -17% |
| 2022 | $169.8 | $144.1 | -15% |
| 2023 | $144.1 | $142.6 | -1.1% |
| 2024 | $142.6 | $163.0 | +14% |
| 2025 | $163.0 | $98.5 | -40% |
| 2026 YTD | $98.5 | $108.2 | +9.8% |
CLX has finished lower in four of the last six years. It's up 9.8% so far in 2026.